Education
About Us
Working with TipRanks
Follow Us
Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
CAI Stock Chart & Stats
$19.38
--
Market closed
$19.38
--
Day’s Range― - ―
52-Week Range$17.15 - $42.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.28M
Market Cap
$5.61B
Enterprise Value$5.18B
Total Cash (Recent Filing)$800.09M
Total Debt (Recent Filing)$378.99M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding282,146,900
10 Day Avg. Volume2,402,943
30 Day Avg. Volume2,281,575
Financial Highlights & Ratios
PEG Ratio2.83
Price to Book (P/B)78.14
Price to Sales (P/S)55.55
P/FCF Ratio674.37
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue6.38
Enterprise Value/Gross Profit9.62
Enterprise Value/Ebitda1.23K
Forecast
1Y Price Target
$40.67Price Target Upside109.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.26
Revenue Forecast (FY)$984.10M
Bulls Say, Bears Say
Bulls Say
Diagnostic PipelineEncouraging interim clinical results for the multi-cancer detection test and a commercial partnership to expand distribution suggest meaningful upside from future diagnostic launches.
Earnings GuidanceManagement provided revenue guidance above consensus, indicating stronger-than-expected top-line momentum that could lift investor confidence.
Proprietary Data And AIA large proprietary tumor-profile dataset combined with advanced AI capabilities strengthens the ability to develop differentiated tests and support long-term product innovation.
Bears Say
Accounting AdjustmentsPart of the reported revenue growth was driven by accounting true-ups from prior periods, which may overstate the pace of underlying business expansion and complicate performance comparisons.
Market And Competitor VolatilityShares are exposed to volatility from competitor volume swings and market sell-offs, increasing execution risk despite the company's guidance.
Operating Expense PressurePlanned expansion of the commercial sales force will increase operating expenses and could weigh on near-term profitability as new hires ramp.
Caris Life Sciences, Inc. News
CAI FAQ
What was Caris Life Sciences, Inc.’s price range in the past 12 months?
Caris Life Sciences, Inc. lowest stock price was $17.15 and its highest was $42.50 in the past 12 months.
What is Caris Life Sciences, Inc.’s market cap?
Caris Life Sciences, Inc.’s market cap is $5.61B.
When is Caris Life Sciences, Inc.’s upcoming earnings report date?
Caris Life Sciences, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 166 days.
How were Caris Life Sciences, Inc.’s earnings last quarter?
Caris Life Sciences, Inc. released its earnings results on Feb 26, 2026. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.049 by $0.231.
Is Caris Life Sciences, Inc. overvalued?
According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Undervalued.
Does Caris Life Sciences, Inc. pay dividends?
Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here
What is Caris Life Sciences, Inc.’s EPS estimate?
Caris Life Sciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc. has 282,146,900 shares outstanding.
What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?
Caris Life Sciences, Inc. reported an EPS of $0.28 in its last earnings report, beating expectations of $0.049. Following the earnings report the stock price went up 4.678%.
Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?
Currently, no hedge funds are holding shares in CAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caris Life Sciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.67 (109.86% Upside)
$40.67 (109.86% Upside)
Blogger Sentiment
Neutral
CAI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.6%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Bullish
Bullish news 79%
Bearish news 21%
Bearish news 21%
Fundamentals
Return on Equity
-45.37%
Trailing 12-Months
Asset Growth
227.48%
Trailing 12-Months
Company Description
Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
CAI Company Deck
CAI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial momentum: very high revenue growth, substantial margin expansion, multiple quarters of positive adjusted EBITDA and free cash flow, a large and growing genomic data asset, and encouraging interim MCED (Caris Detect) results (AUC 0.90, Stage I/II sensitivity 63.1%). Management outlined committed reinvestment in commercial expansion, R&D and MCED capacity while maintaining positive cash flow. Key risks and near-term uncertainties include the interim nature of MCED data (blinded validation and ACHIEVE-2 pending), reimbursement and ASP variability, a meaningful increase in OpEx and CapEx for 2026, and uneven pharma revenue cadence. On balance, the positive financial performance, strong cash position and promising product pipeline outweigh the listed risks.View all CAI earnings summariesCAI Stock 12 Month Forecast
Average Price Target
$40.67
▲(109.86% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---